contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vitrolife-ab-publ-interim-report-q2-2023-strong-growth-in-apac

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vitrolife is an international group that provides medical devices and genetic services. The company develops and manufactures services and products for personalized genetic information as well as medical devices in the field of fertility. Vitrolife supports customers in their operations to improve patient outcomes from fertility treatments. Vitrolife's products and services are available globally. The company is headquartered in Gothenburg, Sweden.

Vitrolife

Second quarterSales of SEK 905 (829) million, an increase of 9%, or 10% excluding discontinued business. In local currencies the growth was 3% and excluding discontinued business 4%.Sales, in...

Second quarter<ul><li>Sales of SEK 905 (829) million, an increase of 9%, or 10% excluding discontinued business. In local currencies the growth was 3% and excluding discontinued business 4%.</li><li>Sales, in local currencies and excluding discontinued business, increased by 19% in APAC, and 3% in EMEA, while sales in Americas decreased by 6%.</li><li>Sales, in local currencies and excluding discontinued business, increased by 17% in Consumables, Technologies decreased by 7% and Genetic Services decreased by 4%.</li><li>Gross margin was 55.8% (56.8), negatively impacted by non-recurring costs of SEK 6 million, giving a run-rate gross margin of 56.5%.</li><li>Operating income before depreciation and amortisation (EBITDA) was SEK 293 (273) million. Adjusted for non-recurring costs, EBITDA was SEK 299 million, giving an EBITDA margin of 33.0% (32.9).</li><li>Operating cash flow increased to SEK 211 million (180).</li><li>Net income was SEK 106 (130) million, including non-recurring costs, resulting in earnings per share of SEK 0.78 (0.96).</li></ul>&nbsp;First half year<ul><li>Sales of SEK 1,759 (1,581) million, an increase of 11%, or 13% excluding discontinued business. In local currencies, growth was 5% and excluding discontinued business 6%.</li><li>Sales, in local currencies and excluding discontinued business, increased by 21% in APAC, 2% in EMEA and 0% in Americas.</li><li>Sales, in local currencies and excluding discontinued business, increased by 14% in Consumables, Technologies growth was 0% and Genetic Services increased by 1%.</li><li>Gross margin increased to 56.3% (56.2).</li><li>Operating income before depreciation and amortisation (EBITDA) was SEK 554 (501) million. Adjusted for non-recurring costs of SEK 26 million, EBITDA was SEK 580 (501) million, giving an EBITDA margin of 33.0% (31.7).</li><li>Operating cash flow increased to SEK 372 million (270).</li><li>Net income was SEK 205 (213) million, including non-recurring costs, resulting in earnings per share of SEK 1.52 (1.56).</li></ul>Gothenburg, July 14, 2023 VITROLIFE AB (publ) Jón Sigurdsson, interim CEOThis disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 14-07-2023 08:00 CET.